BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 19, 2012
 |  BioCentury  |  Strategy

Dissimilar priorities

Pfizer exits insulin biosimilars with Biocon to focus on antibodies, proteins

In the midst of pharma and big biotech's charge into biosimilars, Pfizer Inc. has apparently concluded that mAbs are higher-value opportunities than insulin products. Last week the pharma and Biocon Ltd. ended a deal for biosimilar insulins because Pfizer's priorities have changed.

Under the 2010 deal, Pfizer received rights to market Biocon's portfolio of biosimilar insulin products, including insulin and insulin glargine. Biocon retained co-exclusive rights to the products in Germany, India and Malaysia. Pfizer had exclusive rights elsewhere, except in emerging markets where the pharma shared co-exclusive rights with Biocon's regional partners (see BioCentury, Nov. 15, 2010).

Pfizer has now returned those rights and instead will focus on a biosimilars pipeline that includes five preclinical mAbs it is developing on its own, and an in-licensed enzyme replacement therapy.

"We are prioritizing our efforts on those areas that have the greatest opportunity for creating value for the company, including monoclonal antibodies and recombinant protein products," company spokesperson Joan...

Read the full 782 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >